2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

5880 DHODH inhibition sensitizes hematologic malignancies to CD5 CAR T-cell therapy via CD5 upregulation

Yuxuan Liu, PhD, Ao Wang, PhD2, Milton Merchant3, Pablo Domizi, PhD4, Astraea Jager5, Kylie A Burdsall6, Elena Sotillo, PhD7, Ruida Hou, MD, PhD8, Jun J. Yang, PhD9, Sharon Pitteri10, Crystal Mackall, MD11, Kara L. Davis, D.O.12
1 Stanford University, Stanford, California, United States
2 Stanford University, Stanford, California, United States
3 Stanford University, Stanford, California, United States
4 Stanford University, Stanford, California, United States
5 Stanford University, Stanford, California, United States
6 Stanford University, Stanford, California, United States
7 Stanford University, Stanford, California, United States
8 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
9 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
10 Stanford University, Stanford, California, United States
11 Stanford University, Stanford, California, United States
12 Stanford University, Stanford, California, United States

 Background: CD5 is a surface glycoprotein involved in antigen receptor signaling and serves as both a diagnostic biomarker and therapeutic target in T-cell acute lymphoblastic leukemia (T-ALL), chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL). During thymopoiesis, CD5 expression increases with T-cell maturation. Dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine biosynthesis, has emerged as a promising therapeutic target in acute leukemia. DHODH inhibition also sensitizes tumors to immune checkpoint blockade by increasing MHC class I antigen presentation and upregulates immunotherapy target antigens such as CD38 in AML and multiple myeloma. However, whether DHODH inhibition similarly modulates surface expression of lineage antigens used for CAR T-cell targeting in T-ALL and mature B-cell malignancies remains unexplored.

Methods: Mass cytometry (CyTOF) was used to quantify DHODH expression in primary leukemia samples and healthy hematopoietic populations. Public thymic datasets and T-ALL subtype annotations were analyzed to characterize CD5 expression. T-ALL, CLL, and MCL cell lines were treated with DHODH inhibitors, and CD5 expression was assessed by flow cytometry. To determine whether DHODH inhibitor-induced CD5 upregulation enhances CD5-directed immunotherapy, CD5 CAR T cells were generated following CRISPR-mediated CD5 knockout. T-ALL and MCL cell lines were pretreated with DHODH inhibitor for 72 hours, followed by drug washout prior to co-culture with mock or CD5 CAR T cells.

Results: Analysis of normal thymic development demonstrated low CD5 expression in early thymocytes with progressive upregulation during maturation. Consistent with this developmental pattern, CD5 expression varied across T-ALL genomic subtypes, with the highest expression observed in TAL1-driven leukemias and lower expression in ETP-like, TLX1, and TLX3 subtypes.

CyTOF profiling revealed significantly higher DHODH expression in primary T-ALL blasts than in T-ALL cell lines, B-ALL blasts, and activated T cells. Pharmacologic DHODH inhibition induced greater cytotoxicity in ALL cells than in activated T cells, suggesting a potential therapeutic window for selectively targeting leukemia cells while preserving T cell viability. Across six T-ALL cell lines, DHODH inhibition increased CD5 expression intensity by up to 2.5-fold and increased the frequency of CD5-positive cells by up to 4.5-fold (n = 6, p = 0.032). These effects were completely reversed by uridine supplementation, demonstrating that CD5 upregulation is dependent on pyrimidine depletion. Similar CD5 upregulation was observed in multiple CLL and MCL cell lines, suggesting that this mechanism extends beyond T-ALL.

Because antigen density is a critical determinant of CAR T-cell efficacy, we next investigated whether DHODH inhibitor-mediated CD5 upregulation enhances CD5 CAR T-cell activity. DND41 cells, a CD5-low and DHODH inhibitor-resistant T-ALL model, were treated with DHODH inhibitor or vehicle prior to co-culture with mock or CD5 CAR T cells. DHODH inhibition enhanced CD5 CAR T-cell cytotoxicity at both 1:1 and 1:5 effector-to-target ratios (E:T), with the greatest enhancement observed at the lower 1:5 E:T, where DHODH inhibition reduced the proportion of surviving GFP-positive leukemia cells from 83.4% in vehicle-treated cultures to 5.7% following treatment. In contrast, mock T cells exhibited minimal cytotoxicity against vehicle-treated cells (93.0% GFP-positive cells remaining) but demonstrated increased killing of DHODH inhibitor-treated cells (46.9% GFP-positive cells remaining), suggesting that DHODH inhibition may induce additional immunomodulatory changes beyond CD5 upregulation. Comprehensive surfaceome mass spectrometry profiling is ongoing to define the immune remodeling induced by DHODH inhibition.

Conclusions: These findings identify a previously unrecognized link between pyrimidine metabolism and CD5 surface expression across lymphoid malignancies. Beyond its direct cytotoxic activity, DHODH inhibition remodels the immune phenotype of leukemia cells, increasing susceptibility to T-cell-mediated immune recognition and markedly potentiating CD5 CAR T-cell cytotoxicity. These findings provide a rationale for combining DHODH inhibition with CD5-directed CAR T-cell therapy as a novel immunometabolic strategy for T-ALL and other CD5-positive hematologic malignancies.

Yuxuan Liu, PhD: No relevant conflicts of interest to declare.